Takeda Pharmaceutical Company will hold two meetings for scientific exchange, knowledge sharing regarding Hodgkin Lymphoma.
The meetings consist of a regional summit which will be conducted on the 17th of January and will be followed on the 18th of January by a Centre of Excellence in the Bone Marrow Transplantation Unit of the Air force Specialised Hospital. The two meetings will be attended by the world’s leading experts from Germany, Denmark, Spain, and different Arab and African countries along with our Egyptian experts.
Former president of Cairo University and pioneer of “Bone Marrow Transplant” in Egypt, Dr Hossam Kamel, confirmed that Hodgkin lymphoma can be detected and treated in its early stages, especially in view of recent developments by relying on targeted therapy, immunotherapy, and marrow transplant operations, adding that the world is heading toward establishing standards and recommendations on how to ration the use of chemotherapy in the treatment of this disease in order to avoid its negative side effects.
Director of the Middle East and North Africa, Takeda Medical Department, Dr Iman Gamal added that the programme aims to raise the level of medical services provided to Egyptian patients from diagnosis to treatment and follow-up. She clarified that the scientific platform conducted on January 17 is in cooperation with the Egyptian Haemato-oncology Group (EHOG) which will honour Dr Ayman Mekkawy for his media efforts to increase health awareness among Egyptian society through one of the leading satellite channels.